|
1
|
Cremolini C, Loupakis F, Antoniotti C,
Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M,
Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment of patients with metastatic
colorectal cancer: Updated overall survival and molecular subgroup
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.
16:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maurel J and Postigo A: Prognostic and
predictive biomarkers in colorectal cancer. From the preclinical
setting to clinical practice. Curr Cancer Drug Targets. 15:703–715.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilhelm SM, Dumas J, Adnane L, Lynch M,
Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY
73–4506): A new oral multikinase inhibitor of angiogenic, stromal
and oncogenic receptor tyrosine kinases with potent preclinical
antitumor activity. Int J Cancer. 129:245–255. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sartore-Bianchi A, Siena S, Tonini G,
Bardelli A and Santini D: Overcoming dynamic molecular
heterogeneity in metastatic colorectal cancer: Multikinase
inhibition with regorafenib and the case of rechallenge with
anti-EGFR. Cancer Treat Rev. 51:54–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winder T and Lenz HJ: Vascular endothelial
growth factor and epidermal growth factor signaling pathways as
therapeutic targets for colorectal cancer. Gastroenterology.
138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gherardi E, Birchmeier W, Birchmeier C and
Woude G Vande: Targeting MET in cancer: Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitra AK, Sawada K, Tiwari P, Mui K, Gwin
K and Lengyel E: Ligand-independent activation of c-Met by
fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion
and metastasis. Oncogene. 30:1566–1576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dulak AM, Gubish CT, Stabile LP, Henry C
and Siegfried JM: HGF-independent potentiation of EGFR action by
c-Met. Oncogene. 30:3625–3635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varkaris A, Gaur S, Parikh NU, Song JH,
Dayyani F, Jin JK, Logothetis CJ and Gallick GE: Ligand-independent
activation of MET through IGF-1/IGF-1R signaling. Int J Cancer.
133:1536–1546. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee J, Jain A, Kim P, Lee T, Kuller A,
Princen F, In-Gu Do, Kim SH, Park JO, Park YS, et al: Activated
cMET and IGF1R-driven PI3K signaling predicts poor survival in
colorectal cancers independent of KRAS mutational status. PLoS One.
9:e1035512014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y,
Ge S and Shen L: Prognostic significance of MET amplification and
expression in gastric cancer: A systematic review with
meta-analysis. PLoS One. 9:e845022014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo B, Cen H, Tan X, Liu W and Ke Q:
Prognostic value of MET gene copy number and protein expression in
patients with surgically resected non-small cell lung cancer: A
meta-analysis of published literatures. PLoS One. 9:e993992014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bardelli A, Corso S, Bertotti A, Hobor S,
Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A,
Zecchin D, et al: Amplification of the MET receptor drives
resistance to anti-EGFR therapies in colorectal cancer. Cancer
Discov. 3:658–673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim LC, Song L and Haura EB: Src kinases
as therapeutic targets for cancer. Nav Rev Clin Oncol. 6:587–595.
2009. View Article : Google Scholar
|
|
16
|
Stabile LP, He G, Lui VW, Thomas S, Henry
C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM and Grandis JR:
c-Src activation mediates erlotinib resistance in head and neck
cancer by stimulating c-Met. Clin Cancer Res. 19:380–392. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lieu C and Kopetz S: The SRC family of
protein tyrosine kinases: A new and promising target for colorectal
cancer therapy. Clin Colorectal Cancer. 9:89–94. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vergani E, Vallacchi V, Frigerio S, Deho
P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA,
Rivoltini L, et al: Identification of MET and SRC activation in
melanoma cell lines showing primary resistance to PLX4032.
Neoplasia. 13:1132–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mueller KL, Hunter LA, Ethier SP and
Boemer JL: Met and c-Src cooperate to compensate for loss of
epidermal growth factor receptor kinase activity in breast cancer
cells. Cancer Res. 68:3314–3322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Booth L, Roberts JL, Tavallai M, Webb T,
Leon D, Chen J, McGuire WP, Poklepovic A and Dent P: The afatinib
resistance of in vivo generated H1975 lung cancer cell clones is
mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Oncotarget. 7:19620–19630. 2016.PubMed/NCBI
|
|
22
|
Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y
and Qu X: Cetuximab-induced MET activation acts as a novel
resistance mechanism in colon cancer cells. Int J Mol Sci.
15:5838–5851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM, Villanueva A, Lachenmayer A and
Finn RS: Advances in targeted therapies for hepatocellular
carcinoma in the genomic era. Nat Rev Clin Oncol. 12:408–424. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Corso S and Giordano S: Cell-autonomous
and non-cell-autonomous mechanisms of HGF/MET-driven resistance to
targeted therapies: From basic research to a clinical perspective.
Cancer Discov. 3:978–992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liska D, Chen CT, Bachleitner-Hofmann T,
Christensen JG and Weiser MR: HGF rescues colorectal cancer cells
from EGFR inhibition via MET activation. Clin Cancer Res.
17:472–482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen QY, Jiao DM, Wu YQ, Chen J, Wang J,
Tang XL, Mou H, Hu HZ, Song J, Yan J, et al: MiR-206 inhibits
HGF-induced epithelial-mesenchymal transition and angiogenesis in
non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Oncotarget. 7:18247–18261. 2016.PubMed/NCBI
|
|
27
|
Luraghi P, Reato G, Cipriano E, Sassi F,
Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM III,
et al: MET signaling in colon cancer stem-like cells blunts the
therapeutic response to EGFR inhibitors. Cancer Res. 74:1857–1869.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith MR, Sweeney CJ, Corn PG, Rathkopf
DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor
AO, et al: Cabozantinib in chemotherapy-pretreated metastatic
castration-resistant prostate cancer: Results of a phase II
nonrandomized expansion study. J Clin Oncol. 32:3391–3399. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scagliotti G, von Pawel J, Novello S,
Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A,
Spigel D, et al: Phase III multinational, randomized, double-blind,
placebo-controlled study of tivantinib (ARQ 197) plus erlotinib
versus erlotinib alone in previously treated patients with locally
advanced or metastatic nonsquamous non-small-cell lung cancer. J
Clin Oncol. 33:2667–2674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bertotti A, Bracco C, Girolami F, Torti D,
Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM and Trusolino
L: Inhibition of Src impairs the growth of met-addicted gastric
tumors. Clin Cancer Res. 16:3933–3943. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Emaduddin M, Bicknell DC, Bodmer WF and
Feller SM: Cell growth, global phosphotyrosine elevation, and c-Met
phosphorylation through Src family kinases in colorectal cancer
cells. Proc Natl Acad Sci USA. 105:pp. 2358–2362. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sen B, Peng S, Saigal B, Williams MD and
Johnson FM: Distinct interactions between c-Src and c-Met in
mediating resistance to c-Src inhibition in head and neck cancer.
Clin Cancer Res. 17:514–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okamoto W, Okamoto I, Yoshida T, Okamoto
K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara
K, et al: Identification of c-Src as a potential therapeutic target
for gastric cancer and of MET activation as a cause of resistance
to c-Src inhibition. Mol Cancer Ther. 9:1188–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshida T, Okamoto I, Okamoto W, Hatashita
E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA and Nakagawa
K: Effects of Src inhibitors on cell growth and epidermal growth
factor receptor and MET signaling in gefitinib-resistant non-small
cell lung cancer cells with acquired MET amplification. Cancer Sci.
101:167–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
